Skip to content
Valbenazine
Ingrezza (valbenazine) is a small molecule pharmaceutical. Valbenazine was first approved as Ingrezza on 2017-04-11. It is used to treat tardive dyskinesia in the USA. The pharmaceutical is active against synaptic vesicular amine transporter.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Ingrezza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Valbenazine tosylate
Tradename
Company
Number
Date
Products
INGREZZANeurocrine BiosciencesN-209241 RX2017-04-11
3 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
ingrezzaNew Drug Application2020-04-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
tardive dyskinesiaD000071057G24.01
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Valbenazine Tosylate, Ingrezza, Neurocrine
109401412040-08-10U-1995
110269312039-08-14U-1995
110269392038-09-18DPU-1995
113115322038-09-18DPU-1995
108571372037-10-10U-1995
108571482037-10-10U-1995
108746482037-10-10U-1995, U-3046
109127712037-10-10U-1995, U-3076
109529972037-10-10U-1995
109939412037-10-10U-1995
110400292037-10-10U-1995
109069022036-12-22DS, DP
109069032036-12-22DS, DP
109198922036-12-22DS, DP
100659522036-10-28DS, DPU-1995
108440582036-10-28DS, DPU-1995
108511032036-10-28DS, DPU-1995
108511042036-10-28DPU-1995
80396272031-04-11DS, DP
83576972027-11-08U-1995
ATC Codes
N: Nervous system drugs
N07: Other nervous system drugs in atc
N07X: Other nervous system drugs in atc
N07XX: Other nervous system drugs in atc
N07XX13: Valbenazine
HCPCS
No data
Clinical
Clinical Trials
120 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Herpes simplexD006561B008463728
Hiv infectionsD015658EFO_0000764B201253617
Herpes genitalisD006558EFO_0007282A60425415
Herpes zosterD006562EFO_0006510B021521413
Cytomegalovirus infectionsD003586EFO_0001062B251124
SchizophreniaD012559EFO_0000692F20314
Psychotic disordersD011618F20.81314
Bell palsyD020330EFO_0007167G51.0123
Varicella zoster virus infectionD0000736181113
InfectionsD007239EFO_0000544112
Show 7 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471C611314
ChickenpoxD002644EFO_0007204B011113
HivD006678O98.7123
NeoplasmsD009369C80112
Postherpetic neuralgiaD051474112
Sexually transmitted diseasesD012749A50-A6422
EncephalitisD00466011
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GliomaD005910EFO_0000520314
Non-small-cell lung carcinomaD00228922
LeukemiaD007938C9522
Epstein-barr virus infectionsD020031EFO_000076922
Cognitive dysfunctionD060825G31.8422
Alzheimer diseaseD000544EFO_0000249F0322
Chronic hepatitis bD019694EFO_0004197B18.1112
GlioblastomaD005909EFO_0000515112
AstrocytomaD001254EFO_0000271112
Waldenstrom macroglobulinemiaD008258C88.011
Show 11 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients8210
Lung neoplasmsD008175C34.9022
Breast neoplasmsD001943EFO_0003869C5011
Ovarian neoplasmsD010051EFO_0003893C5611
MesotheliomaD008654C4511
Malignant pleural effusionD016066J91.011
Hepatitis bD00650911
Pancreatic neoplasmsD010190EFO_0003860C2511
EpendymomaD00480611
Bone marrow transplantationD01602611
Show 4 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acne vulgarisD000152EFO_0003894L7011
Bacterial vaginosisD016585EFO_000393211
Immunologic deficiency syndromesD007153HP_0002721D84.911
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVALBENAZINE
INNvalbenazine
Description
Valbenazine, sold under the trade name Ingrezza, is a medication used to treat tardive dyskinesia. It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2
Identifiers
PDB
CAS-ID1025504-45-3
RxCUI1918219
ChEMBL IDCHEMBL2364639
ChEBI ID
PubChem CID24795069
DrugBankDB11915
UNII ID54K37P50KH (ChemIDplus, GSRS)
Target
Agency Approved
SLC18A2
SLC18A2
Organism
Homo sapiens
Gene name
SLC18A2
Gene synonyms
SVMT, VMAT2
NCBI Gene ID
Protein name
synaptic vesicular amine transporter
Protein synonyms
monoamine neurotransmitter transporter, Monoamine transporter, solute carrier family 18 (vesicular monoamine transporter), member 2, Solute carrier family 18 member 2, synaptic vesicle amine transporter, brain, synaptic vesicle monoamine transporter, brain, VAT2, vesicle monoamine transporter type 2, vesicle monoamine/H+ antiporter, Vesicular amine transporter 2
Uniprot ID
Mouse ortholog
Slc18a2 (214084)
synaptic vesicular amine transporter (Q8CC55)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 220 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
16,548 adverse events reported
View more details